Corbus' top-line data from a 22-patient study of anabasum for the treatment of dermatomyositis demonstrated a "highly clinically meaningful and statistically significant" improvement among patients, Cantor Fitzgerald's Elemer Piros said in a research report. Specifically, the data showed a reduction in CDASI scores from baseline of 9.3 points when treated with anabasum versus 3.7 points for patients who were given a placebo. The data also adds a third clinically validated program to the company's late-stage development pipeline.
Piros maintains an Overweight rating on Corbus' stock with an unchanged $24 price target.
"In addition, encouraging evidence of a dose response was also viewed, where the treatment effect following escalation to 20mg anabasum bid (end of week 4), CDASI improved by 6.3 points (p=0.02)," the analyst also said in the report. "We note that the clinical investigator for the study viewed a five point reduction as clinically meaningful, which was surpassed in the Phase 2 study."
Finally, despite the small size of the study, Corbus' therapy is viewed as a "compelling treatment effect" while additional data and analysis are expected to be detailed at the American College of Rheumatology annual meeting on Nov. 7.
At time of publication, shares of Corbus were up 14. 29 percent at $8.
Related Links:Three Ways To Approach The Cannabis Trade
From A(erie) To Z(ynerba): Biotech Catalysts Lined Up For Second Half Of 2017
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.